Role of Matrix Metalloproteinase-9 in Neonatal Hypoxic-Ischemic Encephalopathy

Abstract

BACKGROUND: Neonatal encephalopathy is a heterogeneous syndrome characterised by signs of central nervous system dysfunction in the newborn. Matrix metalloproteinase-9(MMP-9) increases the blood-brain barrier permeability, and their inhibitors can reduce its damage. MMP-9 has been implicated specifically in cerebral ischemia.
 AIM: To measure serum MMP-9 in neonatal hypoxic-ischemic encephalopathy and evaluate its correlation to the severity of early prediction and treatment.
 METHODS: its case-control study. The serum concentration of MMP-9 was determined by ELISA in 100 hypoxic neonates and 50 healthy neonates of matched age and sex who served as controls.
 RESULTS: In our present study the serum MMP-9 level was significantly higher at p = 0.0001 in hypoxic-ischemic full-term newborns (176.7 ± 68.7 ng/ml)as compared to control newborn (69.4 ± 34.85 ng/ml)and it was significantly higher at p = 0.0075 in hypoxic-ischemic preterm newborn (171.2 ± 132.9 ng/ml) when compared to control newborn (72.54 ± 36.74 ng/ml),also MMP-9 was significantly higher at Sarnat stage III at p = 0.0001.
 CONCLUSION: Serum MMP-9 level was significantly higher in hypoxic-ischemic newborns, and significantly increased with severity, so we suggest that serum MMP-9 level is important for predicting neurological sequel and severity in neonatal encephalopathy.

Neutrophil Extracellular Traps Release following Hypoxic-Ischemic Brain Injury in Newborn Rats Treated with Therapeutic Hypothermia

“…In cases of neonatal HIE, little evidence has shown that the recruitment of peripheral and cerebral immune cells into damaged brain areas play a crucial role in HI brain injury [ 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 ], and the level of neutrophil infiltration following HI is associated with an increase in adverse outcomes [ 26 , 27 , 39 , 40 , 41 ].…”